We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Multiple Myeloma Risk Genes Revealed

By LabMedica International staff writers
Posted on 23 Feb 2018
Print article
Image: A bone marrow biopsy showing plasma cells from a patient with multiple myeloma (Photo courtesy of the American Society of Clinical Oncology).
Image: A bone marrow biopsy showing plasma cells from a patient with multiple myeloma (Photo courtesy of the American Society of Clinical Oncology).
Two genes have been uncovered with apparent ties to inherited multiple myeloma risk, starting from analyses of several large American families that are frequently affected by the complex blood plasma cell cancer.

The high-risk pedigree (HRP) design is an established strategy to discover rare, highly penetrant, Mendelian-like causal variants. Its success, however, in complex traits has been modest, largely due to challenges of genetic heterogeneity and complex inheritance models.

An international team of scientists led by those at the University of Utah School of Medicine (Salt Lake City, UT, USA) used an updated version of a gene mapping method known as shared genomic segment (SGS) to narrow in on commonly altered regions in the genomes of multiple myeloma-prone families or "high-risk pedigrees" (HRP) from Utah. By folding in exome sequence data for nearly 1,000 myeloma-free individuals and more than 1,000 individuals affected by multiple myeloma or a precursor condition known as "monoclonal gammopathy of undetermined significance " (MGUS), the team went on to uncover suspicious changes in two genes, Ubiquitin Specific Peptidase 45 (USP45) and AT-Rich Interaction Domain 1A (ARID1A), that appeared to coincide with multiple myeloma risk.

The team used OmniExpress high-density SNP arrays and sequenced individuals from 11 multiple myeloma HRPs, identified through the Utah Cancer Registry, and applied SGS to find shared regions of the genome on chromosomes 6 and 1 with potential ties to multiple myeloma. The team folded in exome sequence data for 28 individuals from the initial 11 pedigrees, along with 126 exomes from a broader set of 44 multiple myeloma pedigrees from the USA, Canada, and France, to identify rare, potentially deleterious mutations in two genes falling the regions of interest: USP45 and ARID1A.

In an even wider exome sequence collection that encompassed 186 early onset multiple myeloma or familial MGUS cases, 733 cases of sporadic multiple myeloma profiled previously, and 964 unaffected controls, the investigators uncovered additional mutations affecting these genes or other genes falling in the same DNA repair or chromatin remodeling complex pathways as USP45 and ARID1A.

The team noted that “Our myeloma findings demonstrate our high-risk pedigree method can identify genetic regions of interest in large, high-risk pedigrees that are also relevant to smaller nuclear families and overall disease risk. We have developed a strategy for gene mapping in complex traits that accounts for heterogeneity within HRPs and formally corrects for multiple testing to allow for statistically rigorous discovery.” The study was published on February 1, 2018, in the journal Public Library of Science Genetics.

Related Links:
University of Utah School of Medicine

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: The new method could reduce undiagnosed cancer cases in less-developed regions (Photo courtesy of 123RF)

New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis

Globally, more than one billion people suffer from a high rate of missed disease diagnosis, highlighting the urgent need for more precise and affordable diagnostic tools. Such tools are especially crucial... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.